Pharmaceuticals

Stock Code

AOS

Stock Exchange

ax

Advanced Ocular Systems (AOS) is a biotechnology company engaged in the development of ophthalmology products and ophthalmic research. It manufactures and commercialises both refractive and pharmaceutical products for improved treatments for ophthalmic conditions and vision correction by use of devices and surgical procedures. Advanced Ocular Systems was listed on the Australian Stock Exchange on 16 June, 2004.The Company’s head office is based in Nedlands, Western Australia.

Stock Code

CXS

Stock Exchange

ax

ChemGenex Pharmaceuticals (CXS) is an Australia-based biotechnology research and development company engaged in the improving patients' lives through the development of personalised therapeutics in the areas of obesity, cancer, depression and diabetes. CXS was listed on the 10th of July 1986. Its average annual revenue reaches approximately $1 million. Its head office is located in Victoria, Australia and to date; around 40 people are employed in the company. ChemGenex Pharmaceuticals Ltd maintains three key drugs: Quinamed, Ceflatonin and CXS-299.

Stock Code

CST

Stock Exchange

ax

Cellestis Limited (CST) is a company engaged in the development, manufacturing as well as marketing of different medical diagnostic products and scientific research. It is also engaged in the commercialisation and development of the technology products of QuantiFERON for scientific research and medical diagnosis in the world. It has main and principal operations in the US, Europe and Australia. CST was listed on the Australian Stock Exchange on the 24th of April, 2001. Its average annual revenue reaches approximately AUD$10 million.

Stock Code

ANP

Stock Exchange

ax

Antisense Therapeutics Limited (ANP) is an Australian-based company operating mainly in the health care industry. Antisense is engaged in the creation, development and commercialisation of the antisense pharmaceuticals. Its principal activity involves utilisation of the antisense technology for the development of therapeutics for human diseases with main operations in Australia, US, Japan and Europe. ANP was listed on the Australian Stock Exchange on the 20th of December 2001. Its average annual revenue reaches approximately AUD$486 thousand out of its issued capital of $39 million.

Stock Code

AGX

Stock Exchange

ax

Agenix (AGX) is an Australian-based company engaged in the research and development of biotechnology. Agenix provides development of the innovative monoclonal antibodies medical products. AGX was listed on the Australian Stock Exchange on the 8th of October 1987. Its average annual revenue reaches approximately AUD$1 million. Its headquarters is located in Queensland, Australia and to date; around 130 people are employed in the company. It operates mainly through AGEN Biomedical, an AGX wholly owned subsidiary.

Stock Code

ACW

Stock Exchange

ax

Actinogen (ACW) is involved in the commercialisation of bioactive compounds. The company is a broad based biotechnology company specializing in the detection and isolation of soil actinomycetes found in Western Australia and the semi-purification and screening of bioactive compounds produced by these actinomycetes. ACW was listed on the Australian Stock Exchange (ASX) on 16 October, 2007. Actinogen is seeking commercial applications of bioactive compounds from soil actinomycetes found in a range of environments in Western Australia.

Stock Code

ACR

Stock Exchange

ax

Acrux (ACR) is a pooled development fund which invests primarily in pharmaceutical businesses developing new products involving the delivery of pharmaceuticals via the skin. ACR was listed on the Australian Stock Exchange (ASX) on 29 September, 2004. Acrux is engaged in the pharmaceutical research and development industry in the field of dynamic drug delivery, the development and commercialization of healthcare products. Acrux's first product, "EvaMist", has been approved by United States Food and Drug Administration (FDA).

Stock Code

CSL

Stock Exchange

ax

CSL is a biopharmaceutical conglomerate that develops, manufactures and markets products which act as treatment or prevention against human medical conditions. CSL operates globally through subsidiaries of CSL Behring, CSL Bioplasma and CSL Biotherapies. The company operates in 27 countries, with major manufacturing facilities in Australia, Germany, New Zealand, Switzerland and the US and has over 9000 employees.

CSL business operations have three separate divisions: pharmaceuticals and vaccines; plasma products; and research and development.

CSL Pharmaceuticals and Vaccines